DK2983721T4 - Terapeutiske indgivelsesvesikler - Google Patents

Terapeutiske indgivelsesvesikler Download PDF

Info

Publication number
DK2983721T4
DK2983721T4 DK14723513.9T DK14723513T DK2983721T4 DK 2983721 T4 DK2983721 T4 DK 2983721T4 DK 14723513 T DK14723513 T DK 14723513T DK 2983721 T4 DK2983721 T4 DK 2983721T4
Authority
DK
Denmark
Prior art keywords
vesicle
therapeutic administration
therapeutic
administration
administration vesicle
Prior art date
Application number
DK14723513.9T
Other languages
English (en)
Other versions
DK2983721T3 (da
Inventor
Joel NORDIN
Edvard Smith
Karl-Henrik Grinnemo
Oscar Simonson
Andaloussi Samir El
Oscar WIKLANDER
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20296661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2983721(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Publication of DK2983721T3 publication Critical patent/DK2983721T3/da
Application granted granted Critical
Publication of DK2983721T4 publication Critical patent/DK2983721T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01C—ROTARY-PISTON OR OSCILLATING-PISTON MACHINES OR ENGINES
    • F01C1/00—Rotary-piston machines or engines
    • F01C1/30—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members
    • F01C1/34—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members
    • F01C1/344—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member
    • F01C1/3441—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member the inner and outer member being in contact along one line or continuous surface substantially parallel to the axis of rotation
    • F01C1/3442—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member the inner and outer member being in contact along one line or continuous surface substantially parallel to the axis of rotation the surfaces of the inner and outer member, forming the working space, being surfaces of revolution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01C—ROTARY-PISTON OR OSCILLATING-PISTON MACHINES OR ENGINES
    • F01C21/00—Component parts, details or accessories not provided for in groups F01C1/00 - F01C20/00
    • F01C21/10—Outer members for co-operation with rotary pistons; Casings
    • F01C21/102—Adjustment of the interstices between moving and fixed parts of the machine by means other than fluid pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Fluid Mechanics (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
DK14723513.9T 2013-04-12 2014-04-10 Terapeutiske indgivelsesvesikler DK2983721T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1300271 2013-04-12
PCT/SE2014/000047 WO2014168548A2 (en) 2013-04-12 2014-04-10 Therapeutic delivery vesicles

Publications (2)

Publication Number Publication Date
DK2983721T3 DK2983721T3 (da) 2018-03-19
DK2983721T4 true DK2983721T4 (da) 2021-02-01

Family

ID=20296661

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14723513.9T DK2983721T4 (da) 2013-04-12 2014-04-10 Terapeutiske indgivelsesvesikler

Country Status (11)

Country Link
US (3) US11274139B2 (da)
EP (2) EP2983721B2 (da)
JP (3) JP6542197B2 (da)
AU (1) AU2014251388B2 (da)
CA (1) CA2910802A1 (da)
DK (1) DK2983721T4 (da)
ES (1) ES2662326T5 (da)
HK (1) HK1257101A1 (da)
PT (1) PT2983721T (da)
SG (1) SG11201508433TA (da)
WO (1) WO2014168548A2 (da)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
AU2014251388B2 (en) 2013-04-12 2017-03-30 Evox Therapeutics Limited Therapeutic delivery vesicles
WO2014170411A1 (en) 2013-04-16 2014-10-23 Orbsen Therapeutics Limited Medical use of syndecan-2
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
CA2949083C (en) 2014-05-18 2023-10-10 Children's Medical Center Corporation Methods and compositions relating to exosomes
GB201418562D0 (en) * 2014-10-20 2014-12-03 Univ London Queen Mary Peptides
WO2016154019A1 (en) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
KR101912315B1 (ko) * 2016-09-30 2018-10-26 주식회사 셀렉스라이프사이언스 Bax 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
US10702581B2 (en) 2015-05-04 2020-07-07 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
US12133879B2 (en) 2015-05-04 2024-11-05 Ilias Biologics Inc. Exosomes for target specific delivery and methods for preparing and delivering the same
KR101877010B1 (ko) * 2016-09-30 2018-08-09 한국과학기술원 super-repressor-IκB 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물
KR101900465B1 (ko) * 2016-10-13 2018-09-19 주식회사 셀렉스라이프사이언스 CRISPR-CAS family를 이용한 게놈 에디팅 툴을 엑소솜으로 전달하는 기술
KR101912313B1 (ko) * 2016-09-30 2018-10-26 주식회사 셀렉스라이프사이언스 Cre 재조합 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 표적 유전자의 조건적 녹아웃 대립유전자를 생성하기 위한 조성물
KR20160130937A (ko) * 2015-05-04 2016-11-15 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법
WO2016178532A1 (ko) * 2015-05-04 2016-11-10 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법
KR101912310B1 (ko) * 2016-10-04 2018-10-26 주식회사 셀렉스라이프사이언스 페록시레독신 i 또는 ii 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 항산화용 약학적 조성물
WO2019035057A2 (en) * 2017-08-17 2019-02-21 Cellex Life Sciences, Incorporated EXOSOMES FOR TARGET-SPECIFIC DELIVERY AND METHODS OF PREPARATION AND ADMINISTRATION THEREOF
US20180177727A1 (en) * 2015-06-10 2018-06-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
CA2997811C (en) * 2015-10-01 2021-09-21 University Of Ottawa Exosome packaging of nucleic acids
WO2017054086A1 (en) * 2015-10-01 2017-04-06 Exerkine Corporation Treatment of genetic myopathies using bioengineered exosomes
EP3377078A4 (en) 2015-11-18 2019-09-04 University Of Georgia Research Foundation, Inc. EXTRACELLULAR NERVE CELL VESITEL
EP3922253A1 (en) * 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
GB2552301A (en) * 2016-07-11 2018-01-24 Evox Therapeutics Ltd Metabolic drug loading of EVs
GB2552460A (en) 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
GB2552774A (en) * 2016-07-12 2018-02-14 Evox Therapeutics Ltd EV-Mediated delivery of binding protein-small molecule conjugates
GB2552473A (en) 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
JP2019528674A (ja) * 2016-09-30 2019-10-17 セレックス ライフ サイエンシズ，インコーポレーテッド タンパク質をロードしたエキソソームを含む組成物、並びにその調製及び送達のための方法
KR102120921B1 (ko) * 2017-02-10 2020-06-10 주식회사 일리아스바이오로직스 Gba 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 고셔병 예방 및 치료용 약학적 조성물
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
CN110650728B (zh) * 2017-03-21 2023-06-23 埃索普罗瑟医疗有限公司 含有用于治疗的肿瘤抑制蛋白的天然细胞衍生的囊泡
US20200392219A1 (en) * 2017-05-08 2020-12-17 Trustees Of Tufts College Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof
AU2018266111B2 (en) 2017-05-08 2024-11-07 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
JP7174758B2 (ja) 2017-07-14 2022-11-17 オーブセン セラピューティクス リミテッド Ｃｄ３９間質幹細胞の単離方法と使用
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
CA3072562A1 (en) * 2017-08-15 2019-02-21 Children's Medical Center Corporation Purified mesenchymal stem cell exosomes and uses thereof
US20200206360A1 (en) * 2017-08-17 2020-07-02 Ilias Biologics Inc. Exosomes for target specific delivery and methods for preparing and delivering the same
US20210163930A1 (en) 2017-08-21 2021-06-03 Resurgo Genetics Limited Methods of changing transcriptional output
GB201717446D0 (en) * 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
TR201720642A2 (tr) * 2017-12-18 2019-07-22 Univ Yeditepe Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇
WO2019122282A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
WO2019122279A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
CN111448316B (zh) 2017-12-22 2025-02-14 罗氏创新中心哥本哈根有限公司 新的硫代亚磷酰胺
GB201802163D0 (en) * 2018-02-09 2018-03-28 Evox Therapeutics Ltd Compositions for EV storage and formulation
CA3091478A1 (en) 2018-02-17 2019-08-22 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
EP3758687A4 (en) * 2018-03-01 2022-03-30 Rhode Island Hospital EXOSOME TARGETING OF CD4+ EXPRESSING CELLS
CN112334190B (zh) 2018-04-30 2024-09-20 儿童医学中心公司 间充质基质细胞外排体及其用途
GB201809622D0 (en) 2018-06-12 2018-07-25 Evox Therapeutics Ltd Engineering extracellular vesicles for affinity purification
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
EP3836957A1 (en) 2018-08-14 2021-06-23 Evercyte GmbH Target-specific extracellular vesicles
JP2021536239A (ja) 2018-08-28 2021-12-27 ロシュ イノベーション センター コペンハーゲン エーエス スプライス調節化合物を使用したネオアンチゲン操作
JP7519698B2 (ja) * 2018-10-04 2024-07-22 エクサオゲンウス セラペウティクス，エスエー 抗炎症及び免疫調節特性を有する臍帯血単核細胞に由来する小型細胞外小胞を含む組成物及びそれらを得るためのプロセス
US12496274B2 (en) 2018-11-14 2025-12-16 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
IL269897B2 (en) 2018-11-15 2023-08-01 Sternum Ltd Implementing control flow correctness verification in code intermediate files
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US20210379192A1 (en) * 2019-01-25 2021-12-09 Mantra Bio, Inc. Skeletal muscle targeting moieties and uses thereof
JP7657726B2 (ja) 2019-03-19 2025-04-07 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020231700A1 (en) * 2019-05-11 2020-11-19 Youngsuk Yi Neurotoxin compositions and methods
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
EP3986429A4 (en) * 2019-06-21 2023-07-19 Entelexo Biotherapeutics Inc. PLATFORMS, COMPOSITIONS, AND METHODS OF ADMINISTRATION OF THERAPEUTICS
WO2021034131A1 (ko) * 2019-08-20 2021-02-25 (주)메디톡스 표적 단백질로서 il-1 저해제를 코딩하는 폴리뉴클레오티드를 포함하는 재조합 세포로부터 유래한 세포외 소낭 및 그의 용도
JP7562682B2 (ja) 2020-01-27 2024-10-07 マントラ バイオ，インコーポレイテッド キメラ小胞局在化部分を含む非天然発生の小胞、その産生方法、およびその使用
EP4099984A4 (en) 2020-02-05 2024-05-01 Diadem Biotherapeutics Inc. ARTIFICIAL SYNAPSES
US20230160864A1 (en) * 2020-02-12 2023-05-25 President And Fellows Of Harvard College Methods of measuring and purifying extracellular vesicles
CA3175322A1 (en) * 2020-03-17 2021-09-23 Ohio State Innovation Foundation Designer extracellular vesicles for treating excitotoxicity
CN111529504B (zh) * 2020-03-25 2023-01-10 西安组织工程与再生医学研究所 功能性嵌合凋亡小体及其制备方法和应用
CN111529505B (zh) * 2020-03-25 2023-04-11 西安组织工程与再生医学研究所 功能性嵌合凋亡小体及其制备方法和应用
CN115335079A (zh) * 2020-03-31 2022-11-11 伊利亚斯生物制品公司 基于外泌体递送nf-kb抑制剂的用途
KR102636371B1 (ko) * 2020-04-10 2024-02-19 한국과학기술연구원 신규 재조합 엑소좀 및 그의 용도
KR102341138B1 (ko) 2020-05-31 2021-12-21 주식회사 엑소코바이오 엑소좀의 막단백질 변이체를 포함하는 엑소좀 및 이의 제조방법
CN111588704B (zh) * 2020-07-01 2023-04-11 西安组织工程与再生医学研究所 靶向响应性释放系统及其制备方法和应用
CN111803617A (zh) * 2020-07-16 2020-10-23 卡杜兰(广州)生命基因工程科技有限公司 一种内载微囊的干细胞系统与制备方法
EP4185600A4 (en) 2020-07-24 2024-12-04 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
US12042545B2 (en) 2020-10-14 2024-07-23 The Board Of Trustees Of The University Of Illinois Encapsulated extracellular vesicles
WO2022087505A1 (en) * 2020-10-23 2022-04-28 Strm.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles for treating myeloproliferative neoplasms
KR20220101559A (ko) 2021-01-11 2022-07-19 주식회사 엑소코바이오 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법
KR20220106696A (ko) 2021-01-21 2022-07-29 주식회사 엑소코바이오 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도
WO2022204955A1 (en) * 2021-03-30 2022-10-06 Shenzhen ChuangSheng XinKe Biotechnology Co., Ltd. Method for preparation of exosomes from ipscs and its derivatives for any clinical use thereof
JP2024513087A (ja) 2021-04-07 2024-03-21 アストラゼネカ・アクチエボラーグ 部位特異的改変のための組成物及び方法
US20240191201A1 (en) * 2021-04-23 2024-06-13 Avulotion Ab Extracellular vesicles from mesenchymal stromal cells for treatment of diseases
CN113616811B (zh) * 2021-08-18 2023-12-05 南京中医药大学 一种载脂蛋白修饰的融合型多功能纳米囊泡及其制备方法和应用
US20250223584A2 (en) 2021-12-03 2025-07-10 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
CN120303407A (zh) 2022-05-17 2025-07-11 恩维洛普治疗有限责任公司 用于有效体内递送的组合物和方法
CN114848608B (zh) * 2022-05-17 2024-01-30 东南大学 一种蛋白或多肽递送载体及其制备方法与应用
EP4282951A1 (en) * 2022-05-25 2023-11-29 École Nationale Vétérinaire, Agroalimentaire et de l'Alimentation, Nantes-Atlantique (ONIRIS) Method for obtaining extracellular vesicles from beta cells
US20240018480A1 (en) * 2022-07-15 2024-01-18 ExoTop Theragnostics Inc. Enhancement of extracellular vesicle production by lysosome inhibitor
CN117802045A (zh) 2022-09-30 2024-04-02 北京恩康医药有限公司 一种工程化细胞外囊泡的构建及其应用
CN116327978A (zh) * 2023-04-20 2023-06-27 常州市武进人民医院(常州市第八人民医院) 一种靶向肝星状细胞的血小板外囊泡递药系统、制备方法及其应用
WO2025061875A1 (en) * 2023-09-20 2025-03-27 Exocure Sweden Ab Isolation of vesicles
WO2025102257A1 (zh) * 2023-11-15 2025-05-22 深圳先进技术研究院 一种靶向子宫工程化细胞外囊泡的制备方法及其应用
WO2025148865A1 (en) * 2024-01-08 2025-07-17 Eonve Lab Co., Limited Engineered exosomes for treatment of alopecia and/or canities
WO2025148862A1 (en) * 2024-01-08 2025-07-17 Eonve Lab Co., Limited Engineered exosomes for skin rejuvenation
WO2025172421A1 (en) 2024-02-14 2025-08-21 Astrazeneca Ab Compositions and methods for treatment of huntington's disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326353B1 (en) † 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
JP3693209B2 (ja) * 1996-04-11 2005-09-07 三菱化学株式会社 閉鎖小胞の製造方法
PL343804A1 (en) * 1998-03-31 2001-09-10 Du Pont Pharm Co Pharmaceuticals for the imaging of angiogenic disorders
FR2788780B1 (fr) * 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
US20040241176A1 (en) 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
ATE512982T1 (de) 2001-08-17 2011-07-15 Exothera L L C Verfahren und zusammensetzung zum gezielten einbringen in exosome
KR20050035511A (ko) * 2001-10-13 2005-04-18 아스테리온 리미티드 폴리펩타이드들을 포함하는 글리코실포스파티딜이노시톨
WO2006079068A2 (en) * 2005-01-20 2006-07-27 University Of Rochester Compositions and methods for studying and treating inflammatory diseases and disorders
US8455188B2 (en) 2007-01-26 2013-06-04 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
GB2463401B (en) † 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
CA2748889A1 (en) * 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP3569254B1 (en) 2009-04-17 2022-07-20 Oxford University Innovation Limited Composition for delivery of genetic material
WO2011097633A2 (en) * 2010-02-08 2011-08-11 Board Of Regents, The University Of Texas System Egf receptor mimicking peptides
WO2012087241A1 (en) 2010-12-20 2012-06-28 Agency For Science, Technology And Research Method of purifying exosomes
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20130028895A1 (en) * 2011-07-27 2013-01-31 Gerald Wulf Exosome inhibiting agents and uses thereof
GB201121069D0 (en) 2011-12-07 2012-01-18 Isis Innovation Delivery system
GB201121070D0 (en) * 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
AU2014251388B2 (en) 2013-04-12 2017-03-30 Evox Therapeutics Limited Therapeutic delivery vesicles

Also Published As

Publication number Publication date
US11274139B2 (en) 2022-03-15
HK1257101A1 (en) 2019-10-11
US11649272B2 (en) 2023-05-16
AU2014251388A1 (en) 2015-11-12
JP2019167378A (ja) 2019-10-03
JP6999601B2 (ja) 2022-02-04
US20160137716A1 (en) 2016-05-19
US20230111666A1 (en) 2023-04-13
DK2983721T3 (da) 2018-03-19
JP2016516768A (ja) 2016-06-09
SG11201508433TA (en) 2015-11-27
CA2910802A1 (en) 2014-10-16
ES2662326T3 (es) 2018-04-06
ES2662326T5 (es) 2021-08-04
PT2983721T (pt) 2018-03-13
WO2014168548A3 (en) 2014-12-04
EP2983721B2 (en) 2021-01-20
WO2014168548A2 (en) 2014-10-16
AU2014251388B2 (en) 2017-03-30
WO2014168548A8 (en) 2015-01-29
EP3335721A1 (en) 2018-06-20
EP2983721B1 (en) 2018-02-21
US20200207833A1 (en) 2020-07-02
JP6542197B2 (ja) 2019-07-10
JP2022058390A (ja) 2022-04-12
EP2983721A2 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
DK2983721T4 (da) Terapeutiske indgivelsesvesikler
DK3062849T3 (da) Medikamentadministrationsanordning
HUE046964T2 (hu) Kombinált gyógyászati készítmény
DK3639872T3 (da) Lægemiddeladministrationsanordning
EP2968894A4 (en) MEDICAL CONNECTOR
BR112016009485A2 (pt) Inalador de medicamento
EP3750590C0 (en) THRESHOLD RELEASE ADMINISTRATION CAPSULE
EP3821931C0 (en) ORONASAL PATIENT INTERFACE
EP2922514A4 (en) BI-RADIAL PATIENT INTERFACE
IL240797B (en) Oral formulations of deferasirox
DK2970389T3 (da) Farmaceutiske forbindelser
DK3038674T3 (da) Medikamentafgivelsesindretning
PL3287133T3 (pl) Protono-wiążące polimery do podawania doustnego
DK2767269T3 (da) Terapeutisk anordning
PL2991633T3 (pl) Terapia bakteriofagami
DK3590499T3 (da) Inhalerbare lægemidler
DK3071265T3 (da) Fjederassisteret lægemiddeladministrationsanordning
DK3043845T3 (da) Lægemiddelfremføringsanordning
DK2964193T3 (da) Lægemidler til oral indgivelse
DK3079667T3 (da) Farmaceutiske doseringsformer
DK3003401T3 (da) Farmaceutisk præparat
HUE071419T2 (hu) Gyógyászati szénhidrát készítmény terápiás alkalmazásra
PT2980085T (pt) Compostos farmaceuticamente activos
DK2897588T3 (da) Inhalerbart lægemiddel
DK2983747T3 (da) Lægemiddelindgivelsesindretning